BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:1079-1093. [PMID: 25858208 DOI: 10.1111/apt.13181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Segal JP, Quraishi MN, Bhala N, Brookes MJ. Prevention of COVID-19 in patients with IBD. Lancet Gastroenterol Hepatol 2020;5:639-40. [PMID: 32442546 DOI: 10.1016/S2468-1253(20)30153-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Guariso G, Gasparetto M. Treating children with inflammatory bowel disease: Current and new perspectives. World J Gastroenterol 2017; 23(30): 5469-5485 [PMID: 28852307 DOI: 10.3748/wjg.v23.i30.5469] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
3 Qiu T, Li H, Sun T, Men P, Cui X, Liu C, Zhai S. Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review. J Clin Pharm Ther 2020;45:1134-42. [DOI: 10.1111/jcpt.13196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Benjamin E, Hijji YM. A Novel Green Synthesis of Thalidomide and Analogs. Journal of Chemistry 2017;2017:1-6. [DOI: 10.1155/2017/6436185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
5 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
6 Spagnoli C, Pisani F, Di Mario F, Leandro G, Gaiani F, De' Angelis GL, Fusco C. Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association. Acta Biomed 2018;89:22-32. [PMID: 30561392 DOI: 10.23750/abm.v89i9-S.7956] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 El-Matary W. Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio. Clin Gastroenterol Hepatol 2017;15:148. [PMID: 27552856 DOI: 10.1016/j.cgh.2016.08.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Ghassemi Jahani SA, Karlsson J, Brisby H, Danielsson AJ. Health-related quality of life and function in middle-aged individuals with thalidomide embryopathy. J Child Orthop 2016;10:691-703. [PMID: 27854003 DOI: 10.1007/s11832-016-0797-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn's disease. Ann Gastroenterol. 2017;30:33-44. [PMID: 28042236 DOI: 10.20524/aog.2016.0099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
10 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Millrine D, Kishimoto T. A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders. Trends Mol Med 2017;23:348-61. [PMID: 28285807 DOI: 10.1016/j.molmed.2017.02.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
12 García-cabo C, Morís G. Peripheral neuropathy: An underreported neurologic manifestation of inflammatory bowel disease. European Journal of Internal Medicine 2015;26:468-75. [DOI: 10.1016/j.ejim.2015.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
13 Bermejo F, Guerra I, Algaba A, López-Sanromán A. Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease. Drugs 2018;78:1-18. [PMID: 29139091 DOI: 10.1007/s40265-017-0842-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhu Z, Li M, Shu X, Bai A, Long S, Liu D, Lu N, Zhu X, Liao W. Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients. Clinics and Research in Hepatology and Gastroenterology 2017;41:210-6. [DOI: 10.1016/j.clinre.2016.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
15 Marônek M, Marafini I, Gardlík R, Link R, Troncone E, Monteleone G. Metalloproteinases in Inflammatory Bowel Diseases. J Inflamm Res 2021;14:1029-41. [PMID: 33790618 DOI: 10.2147/JIR.S288280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lin SN, Mao R, Qian C, Bettenworth D, Wang J, Li J, Bruining D, Jairath V, Feagan B, Chen M, Rieder F; Stenosis Therapy and Antifibrotic Research (STAR) Consortium. Development of Anti-fibrotic Therapy in Stricturing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases. Physiol Rev 2021. [PMID: 34569264 DOI: 10.1152/physrev.00005.2021] [Reference Citation Analysis]
17 Li T, Qiu Y, Li X, Zhuang X, Huang S, Li M, Feng R, Chen B, He Y, Zeng Z, Chen M, Zhang S. Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. Front Med (Lausanne) 2020;7:557986. [PMID: 33240902 DOI: 10.3389/fmed.2020.557986] [Reference Citation Analysis]
18 Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016;95:e4239. [PMID: 27472695 DOI: 10.1097/MD.0000000000004239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
19 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019;12:113-22. [PMID: 31406511 DOI: 10.25122/jml-2018-0075] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
21 Bramuzzo M, Stocco G, Montico M, Arrigo S, Calvi A, Lanteri P, Costa S, Pellegrino S, Magazzù G, Barp J, Ghione S, Lionetti P, Zuin G, Fontana M, Di Chio T, Maggiore G, Lazzerini M, Lucafò M, Udina C, Pellegrin MC, Chicco A, Carrozzi M, Decorti G, Ventura A, Martelossi S. Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2017;23:1810-6. [PMID: 28817461 DOI: 10.1097/MIB.0000000000001195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]